Perioperative systemic therapy and radiotherapy in node-positive penile squamous cell carcinoma

Current evidence on neoadjuvant and adjuvant strategies in the InPACT Er

Auteurs-es

  • Alberto Zambudio-Munuera
  • Patricia Rodriguez-Parras
  • Irene Millan-Ramos
  • Africa Garcia-Navarro
  • Maria Teresa Melgarejo-Segura
  • Francisco Gutierrez-Tejero
  • Ana Donaire-Barrera
  • Miguel Arrabal-Martin
  • Miguel Angel Arrabal-Polo San Cecilio University Hospital

DOI :

https://doi.org/10.5489/cuaj.9802

Mots-clés :

penile cancer; squamous cell carcinoma; neoadjuvant chemotherapy; adjuvant chemotherapy; adjuvant radiotherapy; lymph node metastasis; InPACT; immunotherapy

Résumé

Introduction: Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy in which prognosis is largely determined by nodal involvement. In patients with node-positive disease, surgery alone is frequently insufficient, particularly in the presence of bulky inguinal metastases, pelvic nodal disease, or extranodal extension. Perioperative strategies incorporating systemic therapy and/or radiotherapy have therefore become increasingly relevant, although the evidence base remains limited and predominantly non-randomized. We aimed to critically review the available evidence on neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (ACT), adjuvant radiotherapy (ART), and combined chemoradiotherapy in node-positive PSCC and to contextualize current practice within the framework of contemporary international guidelines and the ongoing InPACT trial.

Methods: Narrative review with structured literature search of PubMed/MEDLINE, EMBASE, Scopus, the Cochrane Library, and ClinicalTrials.gov covering the 15 years preceding the search date, with a targeted update through 2025. Selected phase 2 immunotherapy studies reported in 2025, including full-text publications and conference presentations (ASCO GU 2025 and ESMO 2025), were additionally included as contextual evidence for emerging perioperative strategies.

Results: Cisplatin/taxane-based NAC remains the best-established perioperative approach for selected cN2–N3 patients, with objective response rates of 50–57% and substantially longer survival in clinical responders than non-responders. Retrospective data suggest that ACT may be associated with improved survival in pN3 disease, while ART appears to contribute to locoregional control in patients with extranodal extension, with retrospective data suggesting that dose intensity may influence in-field control. Immunotherapy-based combinations have produced encouraging early-phase signals but remain preliminary and should not yet be regarded as practice-defining.

Conclusions: Current evidence supports cisplatin/taxane-based NAC as the most established perioperative strategy for chemotherapy-fit patients with cN2–N3 PSCC. ACT may be considered mainly in selected pN3 patients or in those with other high-risk pathological features after lymphadenectomy, whereas ART appears most relevant for locoregional risk reduction, particularly in the presence of inguinal extranodal extension.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Publié-e

2026-11-20

Comment citer

Zambudio-Munuera, A., Rodriguez-Parras, P., Millan-Ramos, I., Garcia-Navarro, A., Melgarejo-Segura, M. T., Gutierrez-Tejero, F., … Arrabal-Polo, M. A. (2026). Perioperative systemic therapy and radiotherapy in node-positive penile squamous cell carcinoma: Current evidence on neoadjuvant and adjuvant strategies in the InPACT Er. Canadian Urological Association Journal, 21(3). https://doi.org/10.5489/cuaj.9802

Numéro

Rubrique

Review